Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Katayama K et al. BMJ Open. 2015 Jan 8;5(1):e007330. doi: 10.1136/bmjopen-2014-007330.
Multiple Myeloma Yields to CD38 Inhibitors. [No authors listed]. Cancer Discov. 2015 Jan 16. [Epub ahead of print]. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Atrash S et al. Blood Cancer J. 2015 Jan 16;5:e272. doi: 10.1038/bcj.2014.93. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant. Mangiacavalli S et al. Leuk…
DetailsPomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02. Leleu X et al. Blood. 2015 Jan 9. pii: blood-2014-11-612069. [Epub ahead of print]. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Puig N et al. Leukemia. 2015 Jan 8. doi: 10.1038/leu.2015.7. [Epub ahead of print]. Combined immune checkpoint protein blockade…
DetailsPlasmapheresis in cast nephropathy: yes or no? Madore F. Curr Opin Nephrol Hypertens. 2015 Jan 14. [Epub ahead of print]. Antimicrobial peptides: an alternative for innovative medicines? da Costa JP et al. Appl Microbiol Biotechnol. 2015 Jan 15. [Epub ahead of print]. Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. Zadnik PL et al. J…
DetailsConsensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Arroz M et al. Cytometry B Clin Cytom. 2015 Jan 23. doi: 10.1002/cyto.b.21228. [Epub ahead of print]. Novel agents have a significant impact on survival of patients with multiple myeloma. Lamm W et al. Wien Klin Wochenschr. 2015 Jan 22. [Epub ahead of print]. Multiple myeloma. Mehta A. Hematology. 2015 Jan;20(1):58-9. doi: 10.1179/1024533214Z.000000000333.…
DetailsPleural effusion formation in the course of myeloma. Comert M etal. Arch Bronconeumol. 2015 Jan 22. pii: S0300-2896(14)00242-7. doi: 10.1016/j.arbres.2014.05.009. [Epub ahead of print]. Diagnosis of monoclonal gammopathy of renal significance. Bridoux F et al. Kidney Int. 2015 Jan 21. doi: 10.1038/ki.2014.408. [Epub ahead of print]. Paralytic ileus following “subcutaneous bortezomib” therapy: focus on the clinical emergency-report of two cases. Mele…
DetailsAn open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma. Nishihori T et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12509. [Epub ahead of print]. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myelomanot eligible for or who deferred autologous stem cell transplantation.…
DetailsThe results of a reassessment of the nationally approved list of drugs made available through the Cancer Drugs Fund (CDF) have been announced by NHS England. They confirm that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients; Revlimid as a second-line treatment, and Velcade® as treatment for multiply relapsed Velcade-naive patients will remain on the list whereas…
DetailsHeavy/Light Chain Assay for Monitoring IgA Multiple Myeloma: Digging Out the IgA from the β Region. Calderon B et al. Clin Chem. 2014 Dec 10. pii: clinchem.2014.234757. [Epub ahead of print]. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Mithraprabhu S et al. Epigenetics. 2014 Dec 6:0. [Epub ahead of print]. Calorimetric markers of bence jones and nonsecretory multiple…
DetailsSmoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Manasanch EE et al. Haematologica. 2014 Dec;99(12):1769-71. doi: 10.3324/haematol.2014.107516. Disseminated sclerotic bone lesions with normal 18F-FDG uptake in POEMS syndrome. Shi X et al. Leuk Lymphoma. 2014 Dec 2:1-9. [Epub ahead of print]. Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge.…
Details